Groupe Hospitalier Diaconesses Croix Saint Simon — Clinical Trial Site

104 Registered trials

46 Currently recruiting

Organisation

Groupe Hospitalier Diaconesses Croix Saint Simon

Location

Paris, France

Identifier

ORG-100043407

Address

95 Rue De Reuilly, 75012, France

Departments

2107 Rheumatology
2314 Oncology Medical
Assistance Médicale à la Procréation
Chirurgie Digestive
Department of Internal Medicine
Department of Oncology
Department of Proctology
Gastro-Enterology
Gastroenterology
Infectiologie
Intensive care medicine
Internal medecine
Internal Medicine
Laboratoire de Biologie de la reproduction
Médecine Interne
Médecine Interne et Infectiologie
Médecine interne et rhumatologie
Medical oncology
Medical Oncology - Avron Site
Medical Oncology – Avron Site
Medical oncology department
ONCOLOGIE
Oncologie médicale
ONCOLOGIE OPTION MEDICALE
Oncology
Oncology department
Paris
PROCTOLOGIE
Proctology
Rheumatology
Rhumatologie
Service d'oncologie médicale
Service d’oncologie médicale
Service de Proctologie
Service Medecine Interne
Site Avron - Oncologie médicale
URCEC
Urologie
Urology depatment

Clinical trials at this site (104)

Search interface

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended

2023-508194-89-00 Persistent or Recurrent Rare Epithelial Ovarian Tumors 4 2021-08-30
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Platinum sensitive recurrent ovarian cancer 4 2021-08-05
Improvement of Live Babies Rates After ICSI, Using cpFT Ended

2024-514350-78-00 Infertility 5 2021-07-29
Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended

2023-505615-21-00 Muscle Invasive Bladder Cancer 5 2021-04-28
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac… Ended

2024-510714-32-00 Patiens with locally advanced/metastatic endometrial ca 4 2020-12-10
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
Benefit of a flash dose of corticosteroids in digestive surgical oncology: a randomized, double blind, placebo-controlled trial Ended

2024-513728-40-00 scheduled surgery for digestive cancer 5 2019-07-02
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocri… Ended

2023-505286-84-00 Pancreatic well differentiated neuroendocrine tumors (N 4 2018-06-25
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended

2024-515171-35-00 Prostatic adenocarnicoma with high risk of recurrence 5 2011-07-06
Neoadjuvant pembrolizumab with a watch-and-wait strategy for patients with mismatch repair-deficient or microsatellite instability-high (dMM… Halted

2023-509322-22-00 localized colon cancer 4 2025-11-26
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted

2024-516687-28-00 Patients with GPA and inadequate response to standard o 5 2025-06-06
Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease Ended

2024-519977-20-00 Acute Anterior Ischemic Optic Neuropathy associated wit 4 2025-01-27
SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended

2024-513648-27-00 Patients with newly or active diffuse Systemic sclerosi 4 2024-10-25
Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended

2022-502068-19-00 Moderate to severe rotator cuff tendinopathy 5 2023-11-16
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep… Ended

2024-513230-38-00 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, 5 2022-12-15
Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease… Ended

2024-514347-28-00 Men and women over 18 years of age with renal failure r 5 2022-06-02
A Study to evaluate safety and tolerability of olipudase alfa in pediatric and adult participants with Acid sphingomyelinase deficiency (ASM… Ended

2024-515304-39-00 Niemann-Pick disease 4 2021-11-18
A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended

2023-503813-31-01 Second- or Third-Line Recurrent or Metastatic Cervical 5 2021-09-17